State of Alaska Department of Revenue trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 7.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 49,938 shares of the biotechnology company’s stock after selling 3,892 shares during the quarter. State of Alaska Department of Revenue’s holdings in Exelixis were worth $879,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Point72 Hong Kong Ltd boosted its position in shares of Exelixis by 75.0% in the second quarter. Point72 Hong Kong Ltd now owns 2,411 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 1,033 shares during the period. Quadrant Capital Group LLC boosted its position in shares of Exelixis by 105.2% in the third quarter. Quadrant Capital Group LLC now owns 3,167 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 1,624 shares during the period. CSat Investment Advisory L.P. bought a new stake in shares of Exelixis in the second quarter valued at approximately $153,000. First Mercantile Trust Co. boosted its position in shares of Exelixis by 36.8% in the third quarter. First Mercantile Trust Co. now owns 8,734 shares of the biotechnology company’s stock valued at $154,000 after acquiring an additional 2,348 shares during the period. Finally, Nisa Investment Advisors LLC bought a new stake in shares of Exelixis in the third quarter valued at approximately $162,000. 77.05% of the stock is owned by institutional investors.
In related news, CEO Michael Morrissey sold 25,000 shares of Exelixis stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $17.49, for a total value of $437,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Alan M. Garber sold 86,956 shares of Exelixis stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $18.01, for a total value of $1,566,077.56. Following the completion of the sale, the director now owns 91,329 shares of the company’s stock, valued at $1,644,835.29. The disclosure for this sale can be found here. Over the last quarter, insiders sold 286,956 shares of company stock valued at $5,040,078. Corporate insiders own 4.50% of the company’s stock.
Shares of EXEL stock opened at $19.82 on Friday. The stock has a 50-day moving average price of $18.00 and a 200 day moving average price of $18.62. The company has a quick ratio of 6.80, a current ratio of 6.89 and a debt-to-equity ratio of 0.01. The firm has a market cap of $6.21 billion, a price-to-earnings ratio of 10.16, a PEG ratio of 3.80 and a beta of 1.74. Exelixis, Inc. has a 12 month low of $15.02 and a 12 month high of $25.31.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.31 EPS for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.12. The firm had revenue of $271.70 million during the quarter, compared to analyst estimates of $228.17 million. Exelixis had a return on equity of 25.55% and a net margin of 64.05%. The company’s revenue was up 20.5% on a year-over-year basis. During the same period last year, the company earned $0.44 earnings per share. Sell-side analysts predict that Exelixis, Inc. will post 0.99 earnings per share for the current fiscal year.
Several research firms have recently weighed in on EXEL. BidaskClub raised Exelixis from a “strong sell” rating to a “sell” rating in a research report on Thursday. William Blair reissued a “buy” rating on shares of Exelixis in a research report on Thursday, January 9th. Guggenheim reduced their price objective on Exelixis from $33.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, October 15th. Piper Jaffray Companies reduced their price objective on Exelixis from $45.00 to $35.00 in a research report on Thursday, October 31st. Finally, Bank of America reaffirmed a “buy” rating and issued a $21.00 target price (down from $22.00) on shares of Exelixis in a research report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $25.91.
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Featured Story: How can investors find ex-dividend dates?
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.